Precise Cannabis Dosing Changing the Industry

Whether cannabis is consumed through inhalation or orally, the industry is challenged to provide accurate and precise dosing of CBD and THC.

As both the recreational and medicinal cannabis markets continue to expand, pharmaceutical companies are working on creating the technology that can efficiently break down and quantify the CBD and THC content offering precise cannabis dosing. Through deploying effective dosing techniques, these companies are providing the opportunity for consumers to accurately dose.

Common Issues with traditional dosing

Precise cannabis dosing via edibles and inhalation has been challenging for manufacturers. Where cannabis is legal (recreationally or medicinally) consistent dosing is still a problem within the industry.

Edibles are particularly tricky to dose because a humans stomach acids are what causing the THC to enter the body. Each person’s rate of absorption can differ because of factors such as weight, medical conditions, tolerance, even how much food was consumed that day.

Benefits of precise dosing

In states and countries where medical cannabis is legal, doctors are using guesswork to determine how much cannabis a patient should consume depending on their symptoms.

Lower, more precise cannabis dosing also allow patients and consumers to get the benefits throughout the entire day. This strategy removes any highs and lows. Controlled dosing also leads to more optimized recovery time or a less harsh “coming down” effect.

Innovations for more accurate dosing

Seeing as not all consumers both new users and experienced cannabis enthusiasts are going to desire smoking typical organic plant matter, including those who are uncomfortable with smoking it, the market is already welcoming chewing gums, soda,  mist sprays, to pills, to hospital-grade pharmaceuticals.

The concept of cannabinoids in pill form isn’t new, but it’s appealing from the medicinal side of the sector.

Current Innovative Technologies

AXIM Biotechnologies, Inc. (OTC: AXIM)

AXIM is a biotechnology company, focusing on the treatment of pain, spasticity, anxiety, and other medical disorders with the application of cannabinoids based products. It also focuses on the research, development, and production of pharmaceutical, nutraceutical, oral health, and cosmetic products, as well as procurement of genetically and nano-controlled active ingredients.

GW Pharmaceuticals plc (NASDAQ: GWPH)

GW is a biopharmaceutical company, engaging in discovering, developing, and commercializing cannabinoid prescription medicines derived from the Cannabis plant.

The Hydropothecary Corporation (TSX.V: THCX) (OTC: HYYDF)

The Hydropothecary Corporation is an authorized licensed producer and distributor of medical cannabis licensed by Health Canada under the Access to Cannabis for Medical Purposes Regulations (Canada).

Novartis AG (NYSE: NVS)

Novartis AG researchers create, manufactures, and markets a range of healthcare products throughout the world. The Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in the areas of cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, pain, and respiratory.